Introduction
First generation 'typical' antipsychotics are an older class of antipsychotic than second generation 'atypical' antipsychotics. First generation antipsychotics are used primarily to treat positive symptoms including the experiences of perceptual abnormalities (hallucinations) and fixed, false, irrational beliefs (delusions). Second generation antipsychotics are also effective for the positive symptoms of schizophrenia, and it is sometimes claimed that they are more effective than first generation antipsychotics in treating the negative symptoms of schizophrenia. Negative symptoms include a lack of ordinary mental activities such as emotional expression, social engagement, thinking and motivation.
Antipsychotics may cause side effects which can differ depending on which antipsychotic is being administered and on individual differences in reaction to the drug. Reactions may include extrapyramidal side effects; dyskinesias (repetitive, involuntary, and purposeless body or facial movements); Parkinsonism (cogwheel muscle rigidity, pillrolling tremor and reduced or slowed movements); akathisia (motor restlessness, especially in the legs, and resembling agitation); dystonias (muscle contractions causing unusual twisting of parts of the body, most often in the neck). These effects are caused by the dopamine receptor antagonist action of these drugs. Second generation antipsychotics may cause less extrapyramidal side effects than first generation antipsychotics. One explanation for differences in producing these side effects is that high potency first generation antipsychotics are usually selective dopamine receptor antagonists with a high affinity for the dopamine receptor and they induce extrapyramidal effects by the blockade of these dopamine receptors. In contrast, second generation antipsychotics generally have a lower affinity for the dopamine receptor and also block serotonin receptors, both mechanisms may play a role in mitigating the effects of dopamine blockade. Amisulpride is an exception to other second generation antipsychotics in that it is a pure dopamine receptor antagonist, however it tends to block dopamine receptors more selectively in the limbic system relative to the nigrostriatal system, which is the site responsible for inducing extrapyramidal symptoms. In addition to amisulpride, olanzapine and quetiapine also tend to selectively block dopamine receptors in the mesolimbic system but target serotonin receptors.
Method
We have included only systematic reviews (systematic literature search, detailed methodology with inclusion/exclusion criteria) published in full text, in English, from the year 2000 that report results separately for people with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder or first episode schizophrenia. Reviews were identified by searching the databases MEDLINE, EMBASE, CINAHL, Current Contents, PsycINFO and the Cochrane library. Hand searching reference lists of identified reviews was also conducted. When multiple copies of reviews were found, only the most recent version was included. Reviews with pooled data are prioritised for inclusion.
Review reporting assessment was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist, which describes a preferred way to present a meta-analysis 1 . Reviews rated as having less than 50% of items checked have been excluded from the library. The PRISMA flow diagram is a suggested way of providing information about studies included and excluded with reasons for exclusion. Where no flow diagram has been presented by individual reviews, but identified studies have been described in the text, reviews have been checked for this item. Note that early reviews may have been guided by less stringent 
Results
We found four reviews that met our inclusion criteria [3] [4] [5] [6] .
Efficacy
• Moderate to high quality evidence suggests a small effect of improved overall symptoms with second generation antipsychotics, particularly olanzapine, amilsulpride and risperidone, compared to first generation antipsychotics, particularly haloperidol (mostly high doses, > 12mg/day), which are not as effective as lower doses.
• Moderate to high quality suggests a small effect of less all-cause study discontinuation with olanzapine, risperidone or amisulpride compared to haloperidol in the short-term. Moderate quality evidence suggests only olanzapine may result in less long-term discontinuation due to drug intolerability or inefficiency.
• Moderate to high quality evidence suggests olanzapine and risperidone may improve cognition more than haloperidol, and moderate quality evidence suggests amisulpride, clozapine and sertindole may improve quality of life more than first generation antipsychotics in general.
Side effects
• Moderate quality evidence suggests a medium effect of less extrapyramidal side effects with second generation antipsychotics, particularly olanzapine and risperadone, than with haloperidol. Clozapine, olanzapine, and risperidone may also produce fewer extrapyramidal side effects when compared to low-potency first generation antipsychotics.
• Moderate quality evidence suggests clozapine, quetiapine and zotepine may be more sedating, and aripiprazole less sedating than haloperidol. Compared with low-potency first generation antipsychotics, only clozapine may be more sedating.
• Moderate to high quality evidence suggests less use of benzodiazapines, anticholinergeric medications, and betablockers with olanzapine than with haloperidol.
• Moderate quality evidence suggests amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, and zotepine may be associated with more weight gain than haloperidol, with no differences when compared to low-potency first generation antipsychotics. Moderate quality evidence suggests more cholesterol change with olanzapine than haloperidol, and more tryglyceride change with amisulpride than haloperidol. Similarly, meta-regression showed a decreasing effect size as the dose of haloperidol or chlorpromazine decreased.
TECHNICAL COMMENTARY
Haloperidol: 23 RCTs, dose range 6-22.5mg/day, b = -0.021 95%CI -0.003 to -0.038
Chlorpromazine: 7 RCTs, dose range 375-1000mg/day, b = -1.14, 95%CI -1.68 to -0.58
These results were unaffected by the removal of trials including treatment resistant patients, those taking sertindole, or long-term trials.
Risks
There was no significant difference in dropout rates (a proxy for tolerance) between second generation antipsychotics and haloperidol in the RCTs that used ≤12 mg/day haloperidol (RD = -0.1%, CI -4.6% to 4.4% p > 0.05), but significantly less participants taking second generation antipsychotics than haloperidol dropped out of RCTs using > 12 mg/day haloperidol (RD = -8.3%, CI -1.3% to 15.2%, p < 0.05). First versus second generation antipsychotics
TECHNICAL COMMENTARY

Consistency in results ‡
Consistency measures within subgroups not reported.
Precision in results §
Precise for efficacy, unable to assess risks (RD).
Directness of results
║
Direct for efficacy of overall first vs. second generation antipsychotics Indirect for risks (proxy measure). 
Clinically relevant improvement
Measured by BPRS or PANSS and translated into CGI-C scores
Second generation antipsychotics resulted in slightly better clinically relevant improvement from baseline to follow-up (6-24 weeks) than first generation antipsychotics;
Based on PANSS scores Range: first generation chlorpromazine-0.1 to second generation olanzapine -2.05 CGI-C conversions: 0 = no change, -1 = threshold for minimal improvement, -2 = much improved
Consistency in results
No measure of consistency is reported.
Precision in results
No measure of precision is reported. 
TECHNICAL COMMENTARY
Summary of evidence
Moderate to high quality evidence (large samples, precise, inconsistent, direct) suggests a small effect of amilsulpride, clozapine, olanzapine and risperidone being more efficacious than first generation antipsychotics for symptoms.
Moderate quality evidence (small samples) suggests amisulpride, clozapine and sertindole may improve quality of life more than first generation antipsychotics.
Moderate quality evidence (inconsistent, some imprecision) suggests a medium effect of fewer extrapyramidal side effects with second generation antipsychotics compared to haloperidol, however only clozapine, olanzapine, and risperidone produce fewer extrapyramidal side effects than low-potency first generation antipsychotics. Amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, and zotepine may be associated with more weight gain than haloperidol, but there may be no differences in weight gain when compared to lowpotency first generation antipsychotics. Clozapine, quetiapine and zotepine were significantly more sedating than haloperidol, and aripiprazole was significantly less sedating. Compared with low-potency first generation antipsychotic drugs, only clozapine was significantly more sedating.
Overall symptoms and relapse
Measured by BPRS or PANSS
Second generation amisulpride showed small effects of being more efficacious for all symptom clusters than first generation haloperidol, perphenazine, fluphenazine, or flupenthixol; Note: subgroup analysis using only non-industry sponsored studies of clozapine showed a reduction in the effect size for overall symptoms to -0.22 (p < 0.05); no differences in effect size were reported for olanzapine and risperidone. No consistent differences in effect size were reported depending on comparator dose (haloperidol at more or less than 12 mg/day or 7.5 mg/day, or chlorpromazine 600 mg equivalents for low-potency first generation drugs). 
Quality of life TECHNICAL COMMENTARY
Risks
All second-generation antipsychotic drugs were associated with fewer extrapyramidal side effects than haloperidol, however, only clozapine, olanzapine, and risperidone were better than low-potency first generation antipsychotics (small to medium effects).
Versus Haloperidol;
Amisulpride First versus second generation antipsychotics Amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, and zotepine were associated with significantly more weight gain than haloperidol, and there were no differences in weight gain when compared to low-potency first generation antipsychotics.
Versus haloperidol;
Amisulpride Clozapine, quetiapine and zotepine were significantly more sedating than haloperidol, whereas aripiprazole was significantly less sedating. Compared with low-potency first generation antipsychotic drugs, only clozapine was significantly more sedating (small effects).
Aripiprazole 
Consistency in results
Authors report considerable heterogeneity in some analyses.
Precision in results
Precise for symptoms, quality of life and relapse (apart from sertindole)
Precise for side effects, apart from extrapyramidal side effects for clozapine, quetiapine, and ziprasidone vs. haloperidol, risperidone vs. low potency drugs, and all sedation comparisons. Unable to assess MD.
Directness of results
Direct for overall first vs. second generation antipsychotics. All other side effects information was rated as low quality due to the small samples involved.
TECHNICAL COMMENTARY
Discontinuation in the study
A small effect of less short-term all-cause discontinuation for second generation antipsychotics compared to first generation antipsychotics;
12 
A small effect of less short-term discontinuation due to inefficacy for second generation antipsychotics compared to first generation antipsychotics;
A small to medium effect of less short-term discontinuation due to intolerability for second generation antipsychotics compared to first generation antipsychotics;
A small to medium effect of less long-term discontinuation due to intolerability for second generation antipsychotics compared to first generation antipsychotics;
5 RCTs, N =1,295, RR = 0.49, 95%CI 0.32 to 0.75, p = 0.001
Individually, only olanzapine caused less long-term discontinuation due to intolerability than haloperidol (RR = 0.31, p < 0.001).
No differences in long-term discontinuation due to inefficacy for second generation antipsychotics compared to first generation antipsychotics;
5 RCTs, N =1,295, RR = 0.66, 95%CI 0.37 to 1.17, p = 0.16
Individually, only olanzapine caused less long-term discontinuation due to inefficacy than haloperidol (3 RCTs, N = 582, RR = 0.51, 95%CI 0.27 to 0.95, p = 0.04). Only industry-sponsored studies significantly favouring second generation antipsychotics (p = 0.001), while independently funded or government funded studies did not, although between groups analysis (QB) was not significant. Industry-sponsored studies more likely favoured second generation antipsychotics (statistics not reported). 
No differences in discontinuation due to non-adherence for second generation antipsychotics compared to first generation antipsychotics;
TECHNICAL COMMENTARY
Trend level, very small improvement in depression symptoms for second generation antipsychotics compared to first generation antipsychotics;
Remission and relapse
Trend level, very small effect of more long-term remission rates for second generation antipsychotics compared to first generation antipsychotics;
Consistency in results
Authors report inconsistency in results.
Precision in results
Precise for all efficacy measures apart from; discontinuation due to inefficacy, intolerability or non-adherence; remission rates; relapse rates for ziprasidone; response rates for amisulpride. Precise for extrapyramidal side effects, akathisia and use of benzodiazapines, imprecise for other side effects.
Directness of results Direct
Explanation of acronyms BPRS = Brief Psychiatric Rating Scale, CGI-C = Clinical Global Improvement-Change, CI = Confidence Interval, g = Hedges' g standardised mean difference, I² = the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance), MD = mean difference, N = number of participants, p = statistical probability of obtaining that result (p< 0.05 generally regarded as significant), PANSS = Positive and Negative Syndrome Scale, QB = test for between group differences (heterogeneity between groups of studies for an outcome of interest), RCT = randomised controlled trials, RD = risk difference, RR = relative risk, SMD = standardised mean difference, vs. = versus Prevalence refers to how many existing cases there are at a particular point in time. Incidence refers to how many new cases there are per population in a specified time period. Incidence is usually reported as the number of new cases per 100,000 people per year. Alternatively some studies present the number of new cases that have accumulated over several years against a person-years denominator. This denominator is the sum of individual units of time that the persons in the population are at risk of becoming a case. It takes into account the size of the underlying population sample and its age structure over the duration of observation.
TECHNICAL COMMENTARY
Reliability and validity refers to how accurate the instrument is. Sensitivity is the proportion of actual positives that are correctly identified (100% sensitivity = correct identification of all actual positives) and specificity is the proportion of negatives that are correctly identified (100% specificity = not identifying anyone as positive if they are truly not).
Mean difference scores refer to mean differences between treatment and comparison groups after treatment (or occasionally pre to post treatment) and in a randomised trial there is an assumption that both groups are comparable on this measure prior to treatment. Standardised mean differences are divided by the pooled standard deviation (or the standard deviation of one group when groups are homogenous) which allows results from different scales to be combined and compared. Each study's mean difference is then given a weighting depending on the size of the sample and the variability in the data. Less than 0.4 represents a small effect, around 0.5 a medium effect, and over 0.8 represents a large effect. 7 Odds ratio (OR) or relative risk (RR) refers to the probability of a reduction (< 1) or an increase (> 1) in a particular outcome in a treatment group, or a group exposed to a risk factor, relative to the comparison group. For example, a RR of 0.75 translates to a reduction in risk of an outcome of 25% relative to those not receiving the treatment or not exposed to the risk factor. Conversely, a RR of 1.25 translates to an increased risk of 25% relative to those not receiving treatment or not having been exposed to a risk factor. A RR or OR of 1.00 means there is no difference between groups. A medium effect is considered if RR > 2 or < 0.5 and a large effect if RR > 5 or < 0. Standardised regression coefficients represent the change being in units of standard deviations to allow comparison across different scales. ‡ Inconsistency refers to differing estimates of effect across studies (i.e. heterogeneity or variability in results) that is not explained by subgroup analyses and therefore reduces confidence in the effect estimate. I² is the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) -0% to 40%: heterogeneity might not be important, 30% to 60%: may represent moderate heterogeneity, 50% to 90%: may represent considerable heterogeneity and over this is considerable heterogeneity. I² can be calculated from Q (chi-square) for the test of heterogeneity with the following formula; 7 § Imprecision refers to wide confidence intervals indicating a lack of confidence in the effect estimate. Based on GRADE recommendations, a result for continuous data (standardised mean differences, not weighted mean differences) is considered imprecise if the upper or lower confidence limit crosses an effect size of 0.5 in either direction, and for binary and correlation data, an effect size of 0.25. GRADE also recommends downgrading the evidence when sample size is smaller than 300 (for binary data) and 400 (for continuous data), although for some topics, these criteria should be relaxed. 9 ║ Indirectness of comparison occurs when a comparison of intervention A versus B is not available but A was compared with C and B was compared with C, which allows indirect comparisons of the magnitude of effect of A versus B. Indirectness of population, comparator and/or outcome can also occur when the available evidence regarding a particular population, intervention, comparator, or outcome is not available and is therefore inferred from available evidence. These inferred treatment effect sizes are of lower quality than those gained from head-tohead comparisons of A and B. 
